Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Gains from Investment Securities (2019 - 2024)

Historic Gains from Investment Securities for Kymera Therapeutics (KYMR) over the last 5 years, with Q4 2024 value amounting to $2.0 million.

  • Kymera Therapeutics' Gains from Investment Securities changed N/A to $2.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$168000.0, marking a year-over-year decrease of 10034.4%. This contributed to the annual value of -$168000.0 for FY2024, which is 10034.4% down from last year.
  • Latest data reveals that Kymera Therapeutics reported Gains from Investment Securities of $2.0 million as of Q4 2024.
  • Kymera Therapeutics' 5-year Gains from Investment Securities high stood at $48.8 million for Q1 2023, and its period low was -$1.9 million during Q3 2024.
  • Its 4-year average for Gains from Investment Securities is $8.6 million, with a median of $1.5 million in 2022.
  • The largest annual percentage gain for Kymera Therapeutics' Gains from Investment Securities in the last 5 years was 5034.83% (2022), contrasted with its biggest fall of 5034.83% (2022).
  • Over the past 4 years, Kymera Therapeutics' Gains from Investment Securities (Quarter) stood at $2.0 million in 2021, then crashed by 50.35% to $998000.0 in 2022, then skyrocketed by 4793.09% to $48.8 million in 2023, then crashed by 96.01% to $2.0 million in 2024.
  • Its last three reported values are $2.0 million in Q4 2024, -$1.9 million for Q3 2024, and -$227000.0 during Q2 2024.